The only currently published RCT designed to evaluate the renoprotective effects of an SGLT2 inhibitor in 4401 people with T2D, CKD, and macroalbuminuria, compared with a placebo, is the CREDENCE study (Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in participants with Diabetic Nephropathy) [67]. This evidence concerns the gene SLC5A2 and chronic kidney disease.